Automating Genetic Testing Specialty Drug Prior Auth

Klivira automates the complex process of **genetic testing specialty drug prior auth**, ensuring rapid approval and patient access to critical therapies identified through genomic insights.

For clinics and health systems managing patients with genetically informed conditions, securing prior authorization for specialty drugs is a significant operational challenge. These therapies, often high-cost biologics or gene therapies, require precise documentation, benefit-side determination, and adherence to evolving payer policies, directly impacting patient care pathways and revenue cycles.

The Intersecting Challenges of Genetic Testing and Specialty Drug PA

Genetic testing, encompassing hereditary cancer panels, prenatal screenings, and pharmacogenomics, frequently identifies the need for highly specialized, often high-cost therapies. These specialty drugs trigger complex prior authorization requirements, often managed by RBMs like eviCore and Avalon Healthcare Services, demanding meticulous clinical documentation and precise benefit-side navigation.

Automated Benefit Determination for Genomic-Guided Therapies

A critical hurdle in genetic testing specialty drug prior auth is accurately determining if a prescribed therapy falls under the medical or pharmacy benefit. Klivira's platform automates this classification per drug, per payer, and per patient context, preventing misrouted submissions and accelerating the path to therapy for conditions identified through genomic insights.

Klivira's Streamlined Workflow for Genetic Testing Specialty Drug PA

Automated benefit-side determination for specialty drugs, ensuring submission via the correct medical or pharmacy channel.
Multi-channel routing using NCPDP SCRIPT ePA for pharmacy benefits, or X12 278 and Da Vinci PAS for medical benefits.
Automated extraction of step-therapy and prior-line documentation from FHIR MedicationRequest and Observation resources.
Proactive identification of site-of-care policy mismatches for infused specialty drugs before submission.
Coordinated post-approval handoff to specialty pharmacies, minimizing fulfillment delays for critical medications.
Identification of manufacturer copay-assistance program availability, with clear flags for Medicare-patient exclusions.

Addressing Key Failure Modes in Genetic Testing Specialty Drug PA

Common PA failure points, such as benefit-side misclassification and inadequate step-therapy documentation, are magnified by the complexity of novel genomic therapies. Klivira directly mitigates these by automating accurate routing, extracting necessary clinical history from EMRs via SMART on FHIR, and proactively identifying site-of-care policy conflicts.

EMR Integration and Standards for Genomic Specialty Workflows

Klivira integrates seamlessly with EMR systems, leveraging SMART on FHIR to extract relevant clinical data—including medication history, diagnoses, and genetic test results—for genetic testing specialty drug prior auth. This data populates submissions compliant with industry standards like NCPDP SCRIPT, FHIR MedicationRequest, and Da Vinci PAS.

Aligning with Clinical Guidelines for Genomic Drug Approvals

Prior authorizations for specialty drugs, particularly those based on genetic testing, often require documentation aligned with established clinical guidelines such as NCCN for oncology or ASCO recommendations. Klivira's system facilitates the submission of evidence-grounded documentation that meets payer medical policies and RBM requirements, supporting faster approvals.

Frequently asked questions

How does Klivira handle the distinction between genetic testing PA and the subsequent specialty drug PA?

Klivira's platform can manage both. For genetic testing prior auth, it focuses on medical necessity criteria. For specialty drugs prescribed based on those results, it automates the distinct specialty drug PA workflow, including benefit-side determination (medical vs. pharmacy) and appropriate routing.

Which specific genetic testing PA categories benefit most from specialty drug PA automation?

High-volume categories like hereditary cancer panels, prenatal genetic testing leading to specific therapies, and pharmacogenomics-guided drug selections benefit significantly. These often lead to prescriptions for high-cost biologics or targeted therapies requiring rigorous prior authorization.

Does Klivira integrate with RBMs like eviCore or Avalon Healthcare Services for genetic testing specialty drug prior auth?

Yes, Klivira's platform is designed to connect with various payer channels, including those managed by RBMs such as eviCore and Avalon Healthcare Services. This ensures that specialty drug prior authorizations are submitted through the correct, often RBM-specific, pathways.

How does Klivira ensure the correct site of care is documented for infused genetic testing specialty drugs?

Klivira's logic incorporates payer site-of-care policies for medical-benefit specialty drugs. Before submission, the system identifies if the proposed site of care aligns with payer requirements, surfacing potential mismatches and guiding staff toward compliant options.

Can Klivira help with documentation for step therapy requirements for specialty drugs identified via genetic testing?

Absolutely. Klivira leverages FHIR MedicationRequest and Observation resources from your EMR to automatically extract and document prior-line therapy history, ensuring that step-therapy requirements for specialty biologics and targeted therapies are met and clearly communicated to payers.